News
Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback